Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells 10,960 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Vicki L. Sato sold 10,960 shares of the business’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total value of $137,219.20. Following the sale, the director now owns 1,312,391 shares of the company’s stock, valued at approximately $16,431,135.32. The trade was a 0.83 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Vir Biotechnology Price Performance

Shares of Vir Biotechnology stock opened at $12.48 on Thursday. The firm’s fifty day simple moving average is $8.08 and its 200-day simple moving average is $8.31. Vir Biotechnology, Inc. has a 12 month low of $6.56 and a 12 month high of $14.45. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -3.18 and a beta of 0.51.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($1.56) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.51). Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business had revenue of $2.38 million during the quarter, compared to analyst estimates of $5.54 million. During the same quarter in the prior year, the firm posted ($1.22) earnings per share. The company’s revenue for the quarter was down 9.8% compared to the same quarter last year. Analysts anticipate that Vir Biotechnology, Inc. will post -3.36 earnings per share for the current year.

Wall Street Analyst Weigh In

VIR has been the subject of several recent analyst reports. Barclays reduced their price objective on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. HC Wainwright reissued a “buy” rating and issued a $110.00 price target on shares of Vir Biotechnology in a research report on Wednesday, November 20th. Finally, Needham & Company LLC restated a “buy” rating and issued a $19.00 price objective on shares of Vir Biotechnology in a research note on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.40.

Hedge Funds Weigh In On Vir Biotechnology

Several institutional investors have recently added to or reduced their stakes in VIR. Blue Trust Inc. grew its stake in shares of Vir Biotechnology by 143.5% in the 3rd quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after purchasing an additional 2,351 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of Vir Biotechnology during the third quarter worth $56,000. Magnetar Financial LLC purchased a new position in Vir Biotechnology in the 2nd quarter valued at $95,000. Quest Partners LLC increased its stake in Vir Biotechnology by 142.1% in the 2nd quarter. Quest Partners LLC now owns 12,695 shares of the company’s stock valued at $113,000 after buying an additional 7,452 shares during the period. Finally, Captrust Financial Advisors purchased a new position in Vir Biotechnology during the 3rd quarter worth $118,000. Institutional investors and hedge funds own 65.32% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).